Every material Form 8-K Faeth Therapeutics, Inc. has filed with the SEC since September 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Faeth Therapeutics filed a November 9, 2026 corporate presentation with topline results from its single-arm Phase 2 PIK-201 trial of PIKTOR plus paclitaxel in advanced endometrial cancer. The filing says the results are preliminary and that PIKTOR is investigational and not approved, so the data does not yet establish a commercial outlook for shareholders.
Confirmed objective response rate of 33% (12 of 36 efficacy-evaluable patients), with a 10.30.26 efficacy data cut
Preliminary median progression-free survival of 7.4 months (95% CI 5.3, not reached) across 42 treated patients
27 of 42 patients (64%) had a grade 3 or higher treatment-related adverse event, per the 10.23.26 safety data cut
Faeth Therapeutics reported preliminary topline results from its Phase 2 PIK-201 trial of PIKTOR with paclitaxel in 42 treated patients with advanced endometrial cancer, using an October 30, 2026 efficacy data cut. The confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients) and preliminary median progression-free survival was 7.4 months, and the company said the data support advancing to a Phase 3 trial. The results are preliminary, the trial is single-arm, and 64% of patients had a grade 3 or higher treatment-related adverse event.
Confirmed ORR of 33% (12 of 36); unconfirmed ORR of 36% (13 of 36); 44% confirmed ORR (7 of 16) in patients with a PIK3CA mutation
Preliminary median PFS of 7.4 months (95% CI 5.3 to NR); 6-month PFS rate of 62%
64% of patients had a grade 3 or higher treatment-related adverse event; 2 patients (5%) discontinued due to treatment-related adverse events; no treatment-related deaths
Company webcast held November 9, 2026 at 8:00 a.m. ET
Faeth Therapeutics reported a third-quarter 2026 net loss of $20.4 million, or $0.79 per share, compared with $4.6 million, or $3.62 per share, a year earlier, as research and development and general and administrative expenses rose sharply. Cash, cash equivalents and marketable securities reached $174.8 million at September 30, 2026, up from $21.2 million at December 31, 2025, and the company expects topline Phase 2 PIK-201 data by year-end 2026.
Net loss of $20.4 million ($0.79 per share) for the quarter ended September 30, 2026, versus $4.6 million ($3.62 per share) a year earlier
R&D expenses of $11.7 million, up from $2.5 million; G&A expenses of $10.4 million, up from $2.3 million
Cash, cash equivalents and marketable securities of $174.8 million at September 30, 2026, versus $21.2 million at December 31, 2025
Topline results from the Phase 2 PIK-201 trial in endometrial cancer are expected by year-end 2026
Faeth Therapeutics' board increased its size from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director effective immediately. Dr. Schayowitz currently serves as Executive Vice President and Head of Research and Development at Zymeworks Inc., and his board seat comes with a cash retainer and an option to buy 25,000 shares.
Board expanded from six to seven directors; appointment made October 23, 2026, effective immediately
Dr. Schayowitz (age 46) is EVP and Head of Research and Development at Zymeworks Inc. since April 2026
Initial equity award is an option on 25,000 shares under the 2026 Equity Incentive Plan, vesting monthly through the third anniversary of grant
Faeth Therapeutics appointed Karen Vousden, Ph.D., a cancer biologist and company co-founder, as a Class II director effective immediately, after increasing the board from five to six seats. She also joined the Compensation Committee, and will receive a 25,000-share stock option under the company's director compensation program.
Board expanded from five to six directors on September 11, 2026.
Dr. Vousden's term runs until the 2029 annual meeting of stockholders.
Initial grant is an option to purchase 25,000 shares of common stock, vesting monthly through the third anniversary of the grant date.
Dr. Vousden is a Principal Group Leader at The Francis Crick Institute and a director of Bristol Myers Squibb Company since 2018.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Faeth Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →